Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Stocrin opvejer risiciene til antiretroviral kombinationsbehandling af hivsmittede voksne, unge og børn på tre år og derover.
The Committee for Medicinal Products for Human Use (CHMP) decided that Stocrin’ s benefits are greater than its risks in antiviral combination treatment of HIV-infected adults, adolescents, and children three years of age and older.